涎腺分泌性癌：全球13年经验回顾与荟萃分析

Salivary Gland Secretory Carcinoma; Review of 13 Years World-Wide Experience and Meta-Analysis.

作者信息

Yosefof Eyal, Boldes Tomer, Dan Daniel, Robenshtok Eyal, Strenov Yulia, Bachar Gideon, Shpitzer Thomas, Mizrachi Aviram

机构信息

Department of Otorhinolaryngology and Head and Neck Surgery, Rabin Medical Center-Beilinson Hospital, Petach Tikva, Israel.

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

出版信息

Laryngoscope. 2024 Apr;134(4):1716-1724. doi: 10.1002/lary.31123. Epub 2023 Nov 1.

DOI:10.1002/lary.31123

PMID:37909690

Abstract

OBJECTIVES

Secretory Carcinoma is a malignant salivary gland tumor, initially described in 2010. This rare tumor is associated with the translocation t(12;15) (p13;q25), resulting in the fusion gene ETV6-NTRK3. Since this tumor is quite rare, most publications describe only small cohorts of patients. We aimed to investigate the clinical, pathological, and prognostic features of this newly defined malignant entity.

DATA SOURCES

Pubmed, Google Scholar, and Web of Science databases.

REVIEW METHODS

All published articles between 2010 and 2023 were reviewed. Search terms included the terms "Mammary Analogue Secretory Carcinoma" and "Secretory Carcinoma". All articles published in English reporting on Secretory Carcinoma of salivary glands were retrieved.

RESULTS

One-hundred and 12 retrospective articles reporting a total of 674 patients were included, with 52% males and a mean age of 44.9 ± 18.9. The event rate for patients with advanced-stage disease (Stage 3/4) at presentation was 24.1% (95% CI 17.6%-31.9%, I = 9.2%), 14.6% for regional metastases (95% CI 10.5%-20%, I = 12%), and the event rate of distant metastasis was 8.4% (95% CI 5.5%-12.7%, I = 4.2%). Adjuvant radiotherapy was administered for 30.3% of patients (95% CI 24.1%-37.2%, I = 21.5%). The recurrence rate was 19% (95% CI 15.1%-23.8%, I = 5%). Survival outcomes showed a 17.2% death of disease rate for Secretory Carcinoma patients (95% CI 13.5%-21.8%, I = 7.3%).

CONCLUSIONS

Secretory Carcinoma is a rare and relatively newly defined entity arising in the parotid gland most commonly. Characterized as a low-grade tumor, the majority of patients are diagnosed at an early stage, without regional or distant disease, and the prognosis is relatively good.

LEVEL OF EVIDENCE

NA Laryngoscope, 134:1716-1724, 2024.

摘要

目的

分泌性癌是一种恶性唾液腺肿瘤，于2010年首次被描述。这种罕见肿瘤与t(12;15)(p13;q25)易位相关，导致融合基因ETV6-NTRK3。由于该肿瘤非常罕见，大多数出版物仅描述了小样本患者队列。我们旨在研究这种新定义的恶性实体的临床、病理和预后特征。

数据来源

PubMed、谷歌学术和科学网数据库。

综述方法

对2010年至2023年间所有发表的文章进行综述。检索词包括“乳腺样分泌性癌”和“分泌性癌”。检索了所有以英文发表的关于唾液腺分泌性癌的文章。

结果

纳入了12篇回顾性文章，共报告674例患者，其中男性占52%，平均年龄为44.9±18.9岁。初诊时晚期疾病（3/4期）患者的事件发生率为24.1%（95%CI 17.6%-31.9%，I²=9.2%），区域转移的发生率为14.6%（95%CI 10.5%-20%，I²=12%），远处转移的发生率为8.4%（95%CI 5.5%-12.7%，I²=4.2%）。30.3%的患者接受了辅助放疗（95%CI 24.1%-37.2%，I²=21.5%）。复发率为19%（95%CI 15.1%-23.8%，I²=5%）。生存结果显示，分泌性癌患者的疾病死亡率为17.2%（95%CI 13.5%-21.8%，I²=7.3%）。